Comparison of Molecular and Histologic Ultrastaging Methods in Sentinel Lymph Node Analysis from Clinical Stage II Colon Cancers.
Aged
Aged, 80 and over
Colonic Neoplasms
/ metabolism
Female
Gene Expression Regulation, Neoplastic
HT29 Cells
Humans
Immunohistochemistry
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Neoplasm Staging
Prospective Studies
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Sentinel Lymph Node
/ metabolism
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
10
5
2020
Statut:
ppublish
Résumé
Various studies have demonstrated that occult metastases may be present in patients with clinical stage II colon cancer. The objective of this prospective investigation was to compare the performance of molecular analysis and histologic ultrastaging in detecting occult metastases in sentinel lymph nodes (SLNs). SLNs were collected ex vivo during surgery in 29 patients. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assays were constructed. The results were compared with histologic ultrastaging analysis by hemalum and eosin stain and immunohistochemistry on step serial sections. At least 1 SLN was identified in 76% of the cases. The first hemalum and eosin section identified metastases in 23% of the 22 SLNs. Immunohistochemistry identified isolated tumor cells in 24% of the remaining 17 cases. An overall 73% of the SLNs analyzed by qRT-PCR were positive. Four of them were negative for ultrastaging analysis. qRT-PCR is a powerful tool for the detection of occult metastases in colorectal SLN and seems to be more sensitive than histologic ultrastaging analysis. A larger prospective cohort study is necessary to provide further evidence.
Identifiants
pubmed: 31393285
doi: 10.1097/PAI.0000000000000624
pii: 00129039-201908000-00012
doi:
Substances chimiques
Neoplasm Proteins
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM